Wednesday, 18 November 2026European Markets

BENEVOLENTAI Stock Bullish Momentum With A 9% Rise Today

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(VIANEWS) - The Market ended the session with BENEVOLENTAI (BAI.AS) jumping 9% to €0.55 on Thursday, after two consecutive sessions in a row of losses. AEX-Index fell 0.48% to €789.88, after two consecutive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

BENEVOLENTAI's last close was €0.50, 87.86% under its 52-week high of €4.12.

About BENEVOLENTAI

BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

Earnings Per Share

As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-0.47.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -40.97%.

Yearly Top and Bottom Value

BENEVOLENTAI's stock is valued at €0.55 at 21:34 EST, way below its 52-week high of €4.12 and way higher than its 52-week low of €0.49.

Moving Average

BENEVOLENTAI's value is way below its 50-day moving average of €0.72 and way below its 200-day moving average of €1.39.

More news about BENEVOLENTAI (BAI.AS).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 21 Dec 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›